Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 623-628

  Sasaki, Hidefumi ^a   Okuda, Katsuhiro ^a   Kawano, Osamu ^a   Endo, Katsuhiko ^a   Yukiue, Haruhiro ^a   Yokoyama, Tomoki ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

EGFR; Genotype; Kras; Lung cancer; Nras

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; AGED; AMINO ACID SUBSTITUTION; ARTICLE; FEMALE; GENETIC PROCEDURES; GENETICS; GENOTYPE; HUMAN; JAPAN; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AMINO ACID SUBSTITUTION; FEMALE; GENES, RAS; GENETIC TECHNIQUES; GENOTYPE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE;

EID: 38449107131     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.623     Document Type: Article

References (39)

1. Bunn PA Jr and Kato H: Current perspectives in the treatment of non-small cell lung cancer. Semin Oncol 28: 1-2, 2001.
2. Yasuda K, Ayabe H, Ide H and Uchida Y: On behalf of the Japanese Association for Thoracic Surgery: Thoracic and cardiovascular surgery in Japan during 1998. Annual report by the Japanese association for thoracic surgery. Jpn J Cardiothorac Surg 48: 401-415, 1998.
3. Di Fiore PP, Pierce JH, Fleming TP, et al: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH3T3 cells. Cell 51: 1063-1070, 1987.
4. Velu TJ, Beguinot L, Vass WC, et al: Epidermal-growth-factor-dependent transformation by a human EGF receptor protooncogene. Science 238: 1408-1410, 1987. (Pubitemid 18015962)
5. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R and Kloog Y: The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8: 555-565, 2002. (Pubitemid 34193977)
6. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Ins 97: 339-346, 2005. (Pubitemid 40425952)
7. Reynolds SH, Anna CK, Brown KC, et al: Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci USA 88: 1085-1089, 1991. (Pubitemid 21916169)
8. Uchiyama M, Usami N, Kondo M, et al: Loss of heterozygosity of chromosome 12p does not correlate with Kras mutation in non-small cell lung cancer. Int J Cancer 107: 962-969, 2003. (Pubitemid 37429838)
9. Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005. (Pubitemid 40525194)
10. Wittwer CT, Herrmann MG, Moss AA and Rasmussen RP: Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22: 130-138, 1997. (Pubitemid 27036426)
11. Wittwer T, Ririe M, Andrew V, David A, Gungry A and Bali J: The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 22: 176-181, 1997.
12. Nakao M, Janssen JWG, Seriu T and Bartam CR: Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LigthtCycler technology. Leukemia 14: 312-315, 2000. (Pubitemid 30095388)
13. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
14. Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384, 2005.
15. Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006. (Pubitemid 41681596)
16. Thomas RK, Baker AC, de Biasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet (In press).
17. Sasaki H, Kawano O, Endo K, et al: Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206, 2006.
18. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. New Eng J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
19. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci USA 101: 13306-133011, 2004.
20. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005. (Pubitemid 47050841)
21. Sasaki H, Endo K, Mizuno K, et al: EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 51: 135-136, 2006. (Pubitemid 43088635)
22. Bashey A, Gill R, Levi S, Farr CJ, et al: Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implication for the role of N-ras mutation in AML pathogenesis. Blood 79: 981-989, 1992.
23. Yokota S, Nakao M, Horiike S, et al: Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol 67: 379-387, 1998. (Pubitemid 28346351)
24. Kiyoi H, Naoe T, Nakano Y, et al: Prognostic implication of FLT3 and N-ras gene mutations in acute myeloid leukemia. Blood 93: 3074-3080, 1993.
25. Neubauer A, Dodge RK, George SL, et al: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83: 1603-1611, 1994. (Pubitemid 24081575)
26. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE and Hoeffler JP: Ras mutations in human melanoma: a marker of malignant progression. J Investig Dermatol 102: 285-290, 1994.
27. Demunter A, Ahmadian MR, Libbrecht L, et al: A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res 61: 4916-4922, 2001. (Pubitemid 32691910)
28. Omholt K, Kars Berg S, Platz A, Kanter L, Ringborg U and Hansson J: Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 8: 3468-3474, 2002. (Pubitemid 35340723)
29. Cruz F III, Rubin BP, Wilson D, et al: Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63: 5761-5766, 2001. (Pubitemid 37187472)
30. Richardson GE and Johnson BE: The biology of lung cancer. Semin Oncol 20: 105-127, 1993. (Pubitemid 23119086)
31. Sekido Y, Fong KM and Minna JD: Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378: F21-F59, 1998. (Pubitemid 28381125)
32. Robles AI, Linke SP and Harris CC: The p53 network in lung carcinogenesis. Oncogene 21: 6898-6907, 2002. (Pubitemid 35221936)
33. Gearly R, Zhang L, Siegfried JM, Luketich JD and Keohavong P: Comparison of mutations in p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 8: 297-302, 1999. (Pubitemid 29193900)
34. Vahakangas KH, Bennettt WP, Castren K, et al: p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61: 4350-4356, 2001. (Pubitemid 32685758)
35. Toyooka S, Tsuda T and Gazdar AF: The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 21: 229-239, 2003. (Pubitemid 36292965)
36. You M, Candrian U, Maronpot R, Stoner G and Anderson M: Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86: 3070-3074, 1989. (Pubitemid 19129560)
37. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.
38. Ogino S, Kawasaki T, Brahmandam M, et al: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421, 2005. (Pubitemid 41149657)
39. Krypuy M, Newnham GM, Thomas DM, Conron M and Dobrovic A: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6: 295, 2006.